Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirtobrutinib - Loxo Oncology

Next Previous
Drug Profile

Pirtobrutinib - Loxo Oncology

Alternative Names: Jaypirca; LOXO-305; LY 3527727; RXC-005

Latest Information Update: 15 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redx Pharma
  • Developer Eli Lilly and Company; Loxo Oncology
  • Class Amides; Amines; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 09 Dec 2025 Efficacy and adverse events data from a phase-III BRUIN CLL-313 trial in Chronic lymphocytic leukaemia released by Eli Lilly and Company
  • 09 Dec 2025 Eli Lilly and Company expects regulatory approvals for pirtobrutinib in Chronic lymphocytic leukaemia in earlier disease settings in 2026
  • 09 Dec 2025 Efficacy and adverse events data from a phase III BRUIN CLL-313 trial in Chronic lymphocytic leukaemia released by Eli Lilly and Company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top